|
|
| | MC-VC-PABC-DNA31 Basic information |
| Product Name: | MC-VC-PABC-DNA31 | | Synonyms: | MC-VC-PABC-DNA31;Rifamycin VIII, 1',4-didehydro-5'-[4-[[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-1-piperidinyl]-1,4-dihydro-3'-hydroxy-1-oxo- | | CAS: | 1639352-03-6 | | MF: | C77H96N10O21 | | MW: | 1497.64 | | EINECS: | | | Product Categories: | | | Mol File: | 1639352-03-6.mol |  |
| | MC-VC-PABC-DNA31 Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | pka | 4.28±0.70(Predicted) | | form | Solid | | color | Light blue to blue |
| | MC-VC-PABC-DNA31 Usage And Synthesis |
| Uses | MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC. | | IC 50 | Traditional Cytotoxic Agents | | References | [1] Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119. DOI:10.1038/nchem.2635 |
| | MC-VC-PABC-DNA31 Preparation Products And Raw materials |
|